Alex Serafini Strategy: From Personal Pain to Scientific Purpose Dr. pain research at Hopkins and later an MD-PhD at Mount Sinai. Pain became more than biology — it became a personal strategy. “Half the time, in pain, what works in vivo doesn’t translate to clinic. About Alex Serafini Alex was born and raised in the Bay Area and received his BS/MS Neuroscience from

.” – Ben Clements His pivot into neuroscience and pharmacology during grad school at the University of “We’re enhancing the powerful pain-relieving effects of opioids while limiting respiratory depression He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain

later completed postdoctoral training at Creighton University in the Department of Pharmacology and Neuroscience , focusing on neuroactive natural products. Her laboratory investigates marine-derived natural products with neuroactive properties, with particular

Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain

biology into traditionally pharmacology-driven GPCR programs and worked across migraine, cardiovascular, pain Foord led bioinformatics for neuroscience and played a central role in GSK’s early large-scale genetics As Head of Bioinformatics for Neuroscience, Dr.

Then I moved to the University of Oxford on a 4-year Wellcome Trust Scholarship in Neuroscience, through which I gained an M.Sc. from Somerville College and a D.Phil. from Magdalen College Oxford, both in Neuroscience.

Fiona Marshall is VP and Head of Neuroscience Discovery at MSD, leading teams in West Point, Boston, protein stabilization, allosteric modulation, and the pharmacology of receptor families implicated in neuroscience The GABA-B Heterodimer Was Hiding in Plain Sight Dr. She then pursued her Ph.D. in neuroscience at Cambridge University. Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience

Classified GPCR News Let’s dive into the Classified GPCR News from February 10th to 16th, 2025 Industry News Pain hiPSC line (ICADRB2i007-A-3) from an individual with osteoporosis linked to ADRB2: c.46G > A GPCRs in Neuroscience administration in spinal cord injury GPR37L1 identifies spinal cord astrocytes and protects neuropathic pain Neuroregeneration , EPSC , GLT-1 , GPR37L1 , SPM , astrocytes , maresin 1 , microglia , nerve injury , neuropathic pain

Pradhan returns to often: that organisms in chronic pain are fundamentally different biological systems been her scientific focus for nearly two decades, through failed clinical trials in depression and pain Chicago, where her lab studies opioid receptor biology in the context of headache disorders, chronic pain Delta opioid agonists appear to relieve the same symptoms — pain, negative affect, and aura-related signs After failed trials in depression and pain, Dr.

The main goal of the GPCR Retreat is to provide a venue for students, post-doctoral fellows, and principal a special thought for Marc Caron (1946-2022) to commemorate his great contributions to the GPCR and Neurosciences include also world-class and diverse GPCR scientists working in the arenas of structure and signaling, neuroscience

Terry Kenakin’s unique course, Development of GPCR Ligands as Therapeutic Drugs , and gain essential hiPSC line (ICADRB2i007-A-3) from an individual with osteoporosis linked to ADRB2: c.46G > A GPCRs in Neuroscience Cortical astrocyte activation triggers meningeal nociception and migraine-like pain GPCRs in Oncology

coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics breakthrough GPCR research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics , a biotech startup focused on targeting supraspinal GPCRs for chronic pain.

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience

Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia

recurring example: the same molecule promotes opioid antinociception in one context, drives chronic pain the dorsal horn lights up with phospho-ERK in response to opioid, routing through RSK1/2 to stronger pain With a non-selective HSP90 inhibitor given systemically, the brain effect dominates and pain relief is a six-hour feeding window for seven days increased morphine's antinociceptive efficacy in multiple pain The paper is published in Pain , and the translational path is unusually short — you don't need a ten-year

Nigel Bunnett at the NYU Pain Research Center as a postdoctoral researcher. focuses on investigating GPCR signaling and trafficking in the context of inflammation and chronic pain Next Steps Badr will continue focusing his research on GPCRs involved in pain and inflammation during Badr shared his passion for GPCR signalling and regulation, specifically in the context of pain and inflammation

Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain During that time, I investigated the effect of lung cancer-related mutations in the GAIN domain of the

I teach undergraduate Biochemistry and a variety of graduate neuroscience courses.

In 2018 I got married and moved to France, to join the Interdisciplinary Institute for Neurosciences

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain

Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at

Kase, MD Professor in the Departments of Pharmacological Sciences, Neuroscience, and Artificial Intelligence

With my background in neuroscience, the lab of Dr.

neurons), Vollum Institute Portland (visiting scientist with Ed McCleskey, sensory neuron properties); Pain

Endocrine Society of Australia Senior Plenary award, Rand Medal (ASCEPT), Paxinos-Watson Award (Australian Neuroscience

Louis, followed by a Ph.D. in Neurosciences at the University of California, San Diego.

Gainetdinov was a Senior Researcher in the Department of Neuroscience and Brain Technologies at the Italian

He obtained his Ph.D. in Neuroscience from Ohio State University focusing on synaptic plasticity and